Updated:
Walvax
Liu Yi and Li Ge founded Walvax Biotechnology in 2001, taking the company public on the Shenzhen Stock Exchange in 2010.
Walvax
Liu Yi and Li Ge founded Walvax Biotechnology in 2001, taking the company public on the Shenzhen Stock Exchange in 2010. The vaccine maker became a key supplier during China's immunization programs, generating substantial wealth that now flows through this family office. The office is headquartered in Shenzhen, with additional presence in Beijing and Kunming. The family office invests across healthcare services, biotech, real estate, and private credit. It favors direct co-investments alongside Chinese healthcare-focused funds and has deployed capital into hospital operators, diagnostic chains, and medical-device manufacturers (per public announcements, 2022-2023). In real estate, it holds commercial properties in Shenzhen and Kunming. The geographic focus is primarily China, with growing exposure to Southeast Asian healthcare assets. Team size remains undisclosed, though the office is understood to employ fewer than 20 professionals, typical for a single-family office of this scale (Altss estimate). The office does not maintain a public-facing website or LinkedIn presence, consistent with a low-profile posture common among Chinese family offices. In 2023, the office was reported to have increased its allocation to private credit amid China's tightening real estate market (per public records). A structural differentiator is the direct alignment with the operating business — the office's healthcare investments often leverage relationships from Walvax Biotechnology's supply chain and regulatory expertise. This creates deal flow that external funds cannot replicate, particularly in China's regulated vaccine and diagnostics sectors.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shenzhen
Corporate office
Shenzhen, China
Additional offices
Beijing · Kunming
Principals
Liu Yi
Founder
Li Ge
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Walvax?
Liu Yi and Li Ge, the co-founders of Walvax Biotechnology, oversee investment decisions. The office does not publicly disclose a CIO or dedicated investment committee, suggesting the principals remain directly involved (per public record).
How does Walvax source proprietary deal flow?
The office leverages the operating business's supply chain and regulatory expertise in China's healthcare sector. This gives it unique access to hospital operators, diagnostic chains, and medical-device manufacturers that external funds may not reach (per public announcements).
Is Walvax structured as a single family office or does it operate more like a venture firm?
It is structured as a single-family office. The office does not manage external capital and its investments are directly linked to the wealth generated from Walvax Biotechnology, per public filings and typical Chinese family office structures.
Does Walvax participate in fund commitments or only direct deals?
The office is known to participate in direct deals and co-investments, often alongside Chinese healthcare-focused funds. Public records indicate it has not been a limited partner in external funds, staying primarily in direct investments.
What investment stages does Walvax typically target?
The office targets growth-stage healthcare companies and private credit opportunities, with some real estate holdings. There is no evidence of early-stage venture investments or public equities in its portfolio.
Which sectors does Walvax explicitly avoid?
The office avoids technology, cryptocurrency, and energy — preferring healthcare, real estate, and credit where it has direct operating experience. This is inferred from portfolio disclosures and public records.
Where does the underlying wealth come from?
The wealth originates from Walvax Biotechnology, a Chinese vaccine maker co-founded by Liu Yi and Li Ge in 2001. The company went public on the Shenzhen Stock Exchange in 2010, and the family office was established to manage the proceeds (per public filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: